Prophylactic cancer vaccines

Current Opinion in Immunology

Volumn 14, Issue 2, 2002, Pages 172-177

  Finn, Olivera J ^a   Forni, Guido ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANTIBODY; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; HEAT SHOCK PROTEIN 70; MUCIN 1; TUMOR ANTIGEN;

CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; TRANSGENIC MOUSE; TUMOR REJECTION; VACCINATION;

EID: 0036533437     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00317-5     Document Type: Review

References (68)

1. Papillomaviruses and cervical cancer: Pathogenesis and vaccine development
2. Cervical carcinoma and human papillomavirus: On the road to preventing major human cancer
3. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
4. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
5. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine
6. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
7. Do human cancers express shared protective antigens? Or the necessity of remembrance of things past
8. Immunotherapy of human cancer: Lessons from mice
9. Human tumor antigens are ready to fly
10. Cross-reactive cellular and humoral immunity to carcinogen-induced chicken fibrosarcomas. I. Protective cross-immunity between transplantable tumor lines
11. Cross-reactive cellular and humoral immunity to carcinogen-induced chicken fibrosarcomas
12. Vaccination with soluble low-molecular weight tumor-associated proteins suppresses chemically-induced mammary tumorigenesis in rats
13. Tumor-preventive effects of the soluble p53 antigen on chemically-induced skin cancer in mice
14. Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity
15. Breast cancer in mice: Effect of murine Muc-1 immunization on tumor incidence in C3HeOuj mice
16. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein
17. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis
18. CSF-1 promotes progression of mammary tumors to malignancy
19. The immune reaction as a stimulator of tumor growth
20. Inflammation and cancer: Back to Virchow?
21. Inflammatory cells and cancer: Think different!
22. Oncogenic kinase signalling
23. Transgenic mouse models of human breast cancer
24. Interleukin-12 mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
25. Genetic immunization against neu/erbB2 transgenic breast cancer
26. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA
27. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice
28. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
29. DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
30. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine
31. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination
32. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor
33. neu to inhibit mammary carcinogenesis in HER-2/neu transgenic BALB/C mice
34. neu DNA vaccination in Her-2/neu transgenic BALB/c mice
35. Combined allogeneic tumor cell vaccination and systemic IL-12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
36. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
37. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
38. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
39. Vaccination with cytoplasmic Erbb-2 DNA protects mice from mammary tumor growth without anti-Erbb-2 antibody
40. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues
41. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern
42. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy
43. Induction of protective host immunity to carcinoembryonic antigen (CEA), self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virusm
44. Induction of cytotoxic T cells and their anti-tumor activity in mice transgenic for carcinoembryonic antigen
45. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice
46. Epithelial cell mucins
47. Specific, MHC-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells
48. Biology, biochemistry and immunology of carcinoma-associated mucins
49. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
50. Immunity to murine breast cancer cells modified to express MUC1, a human breast cancer antigen, in transgenic mice tolerant to human MUC1
51. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines
52. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice
53. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA
54. Three different vaccines based on the 140 amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1 transgenic mice with different potential for tumor rejection
55. Mice with spontaneous pancreatic cancer naturally develop MUC1-specific CTls that eradicate tumors when adoptively transferred
56. Metastatic prostate cancer in a transgenic mouse
57. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
58. Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-δ12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells
59. Specific and non-specific immunity in the prevention of spontaneous tumors
60. Immunoprevention of cancer: Is the time ripe?
61. Expression of colorectal carcinoma-associated antigens in colonic polyps
62. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression
63. Immunohistochemical study of MUC1 mucin in premalignant oral lesions and oral squamous cell carcinoma: Association with disease progression, mode of invasion and metastasis
64. Tn antigen is a pre-cancerous biomarker in breast tissue and serum in n-nitrosomethylurea-induced rat mammary carcinogenesis
65. Spectrum of carcinoembryonic antigen immunoreactivity from isolated ductal hyperplasias to atypical hyperplasias associated with infiltrating ductal breast cancer
66. Monoclonal antibody therapy for resected Dukes' C colorectel cancer: Seven-year outcome of a multicenter randomized trial
67. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases
68. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic IL-12